DICER1 syndrome and thyroid disease  by Canfarotta, Michael et al.
Contents lists available at ScienceDirect
J Ped Surg Case Reports 11 (2016) 31e34Journal of Pediatric Surgery CASE REPORTS
journal homepage: www.jpscasereports .comDICER1 syndrome and thyroid disease
Michael Canfarotta a,1, Rebecca Riba-Wolman b,2, Andrea D. Orsey c,3,
Fabiola Balarezo d,4, Christine Finck e,*
aUniversity of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06032, USA
bDepartment of Pediatrics and Endocrinology, Connecticut Children’s Medical Center, Multidisciplinary Thyroid Center, 282 Washington Street,
Hartford, CT 06106, USA
cDepartment of Pediatrics and Hematology/Oncology, Connecticut Children’s Medical Center, 282 Washington Street, Hartford, CT 06106, USA
dDepartment of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour Street, P.O. Box 5037, Hartford, CT 06102, USA
eDepartment of Surgery, Connecticut Children’s Medical Center, Multidisciplinary Thyroid Center, 282 Washington Street, Hartford, CT 06106, USAa r t i c l e i n f o
Article history:
Received 13 May 2016
Received in revised form
25 May 2016
Accepted 26 May 2016
Key words:
DICER1
Multinodular goiter
Ovarian Sertoli-Leydig cell tumor
Cancer predisposition syndrome
Pediatric onset tumors* Corresponding author. Tel.: þ1 860 545 9520; fax:
E-mail address: cﬁnck@connecticutchildrens.org (C
1 Tel.: þ1 860 679 7845; fax: þ1 860 679 1201.
2 Tel.: þ1 860 837 6700.
3 Tel.: þ1 860 545 9630.
4 Tel.: þ1 860 972 2249.
2213-5766/ 2016 The Authors. Published by Elsevier
http://dx.doi.org/10.1016/j.epsc.2016.05.014a b s t r a c t
DICER1, a member of the ribonuclease III (RNase III) family, is known to play an important role in the
post-transcriptional regulation of gene expression and germline mutations have been associated with a
familial tumor susceptibility syndrome. In this report, we describe an 11-year-old female with a history
of ovarian Sertoli-Leydig cell tumor resection and known DICER1 mutation (c.325C>T, p.Gln109*). She
presented with multiple thyroid nodules on screening ultrasound. On ﬁne needle aspiration she was
found to have cytologic atypia, which in the general adult population confers a 5e15% risk of malignancy.
Herein, we review the literature on DICER1 phenotype and pediatric thyroid disease and discuss
management options.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).DICER1 is amember of the ribonuclease III (RNase III) family that
is involved in cleaving double stranded pre-microRNAs into mature
micro-ribonucleic acids (miRNAs) [1]. Mature miRNAs are 22
nucleotide, single stranded, noncoding small RNAs that bind to the
30-untranslated region of target mRNAs to suppress their trans-
lation by either silencing or degradation [2]. These molecules
regulate the expression of many cellular proteins. Dysregulation of
miRNAs has been related to cancer initiation and progression for
several tumor types, including all variants of thyroid cancer [2].
DICER1 germline mutations also have been described in association
with multinodular goiter (MNG), Sertoli-Leydig cell tumors (SLCT),
cystic nephroma, pleuropulmonary blastoma, primitive neuro-
ectodermal tumor, cervical embryonal rhabdomyosarcoma, and
Wilms tumor [3e10]. We present a pediatric case of MNG with
atypia of undetermined signiﬁcance on ﬁne needle aspiration (FNA)þ1 860 545 9545.
. Finck).
Inc. This is an open access article uin a patient with a history of ovarian SLCT and conﬁrmed DICER1
syndrome and review the literature on work up and management.1. Case report
An 11-year-old female presented with nine nodules, the largest
being 1  0.8  0.9 cm (Fig. 1), on her thyroid screening ultrasound
following conﬁrmation of a DICER1 mutation (c.325C>T,
p.Gln109*).
Four years previously, she was diagnosed with SLCT of the right
ovary. She underwent an oophorectomy and completed chemo-
therapy including six cycles of PEB (cisplatin, etoposide and bleo-
mycin) as per AGCT0132. She did not receive radiation therapy. She
developed autoimmune hypothyroidism shortly after treatment for
her SLCT and had been maintained on levothyroxine. She had no
family history of thyroid disease and no complaints suggestive of
hyper or hypothyroidism while on levothyroxine. Her physical
exam was unremarkable with no palpable thyroid nodules or
cervical adenopathy. The patient underwent FNA biopsy of the
thyroid nodules, which demonstrated atypia of undetermined sig-
niﬁcance (Bethesda class III). With the reported 5e15% risk for
malignancy, case reports of differentiated thyroid cancer in DICER1nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Ultrasound of the thyroid shows an isoechoic nodule measuring 1  0.8  0.9 cm (white arrows) in the presence of multiple smaller nodules bilaterally (not depicted).
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well as anticipated anxiety associated with repetitive screening in a
patient with prior cancer, the family opted for total thyroidectomy.
Intraoperative pathologic examination showed multiple, well-
circumscribed hyperplastic nodules with some nodules showing
cellular atypia. However, these nodules were not diagnostic for a
follicular variant of papillary carcinoma and most consistent with
MNG (Fig. 2).Fig. 2. Thyroid tissue with hyperplastic/adenomatoid nodules, H&E, 100.2. Discussion
The familial tumor susceptibility syndrome associated with
germline inactivating mutations in DICER1 has only been recog-
nized for the past several years [3]. Heterozygous germline DICER1
mutations, usually in the context of a tissue-speciﬁc mutation on
the other allele, predispose to various tumors, collectively called
DICER1 syndrome [11]. Pleuropulmonary blastoma and SLCT are
two of the characteristic tumors of DICER1 syndrome [11]. In fact,
early results from the International Ovarian and Testicular Stromal
Tumor Registry show germline DICER1 mutations in 48% of girls
and women with SLCT [12]. The exact prevalence of DICER1
mutations is unknown but it is assumed to be a rare condition that
is characteristically inherited in an autosomal dominant manner
with variable penetrance. Genetic counseling is recommended as
each child of an individual with a pathogenic variant of the gene has
a 50% chance of inheriting the variant [13]. To date, nearly ﬁfty
different germline mutations with various neoplasms have been
reported that include nonsense, frameshift, splicing, and missense
mutations along with large gene rearrangements [3e10,14e17].
Our report describes a young female previously diagnosed with
ovarian SLCT that underwent molecular testing conﬁrming a
DICER1 mutation. Several years later the phenotype expanded with
presentation of MNG. The prevalence of MNG is reportedly between3.9% and 6% in school-age children and adolescents and most
frequently associated with chronic lymphocytic thyroiditis [18].
However, in DICER1 syndrome, MNG has been reported to occur
along with differentiated thyroid cancer [11]. Additionally, the FNA
of our patient demonstrated atypia of undetermined signiﬁcance
(Bethesda class III), thus raising concern for possible malignancy.
The new American Thyroid recommendations in adults suggest
lobectomy or repeat FNA in this setting [19]. However, the
Fig. 3. Algorithm for the management of thyroid disease in patients with a known or suspected DICER1 mutation. ATA, American Thyroid Association; FNA, ﬁne needle aspiration.
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shown to be as high as 28% in the pediatric population [20,21],
therefore the most recent guidelines by the American Thyroid As-
sociation recommend surgical intervention in children [22].
Although cases of DICER1 syndrome are more frequently associated
with benign thyroid nodules, thyroid carcinoma has been described
[11,23]. With the potential increased risk, annual physical exam
with or without ultrasound of the thyroid has been recommended
for young children with DICER1 mutations.
This case highlights the challenges faced by the surgeon with
atypical cells found on FNA biopsy in the setting of an unknown
progression to carcinoma given the rarity of the condition. We
provide a suggested algorithm for the management of thyroid
disease with a known or suspected DICER1 mutation (Fig. 3).3. Conclusion
Herein, we present a young female with DICER1 syndrome
diagnosed after treatment for ovarian SLCT which prompted
recognition of MNG. Clinicians should be aware of potential
germline mutations in DICER1 in children presenting with MNG,
ovarian SLCT or pleuropulmonary blastoma and should consider
obtaining genetic testing. Although this rare syndrome is more
often associated with benign nodules, there is a risk for progression
to carcinoma. Our case highlights the importance for these patients
to have an annual physical exam which include surveillance
screening for DICER1 related malignancies such as thyroid and
pelvic ultrasounds. As this syndrome has only been recently
described, surveillance guidelines are not available. Long term
follow-up studies such as the International Ovarian and Testicular
Stromal Tumor Registry through the University of Minnesota are
necessary to improve counseling and treatment.Conﬂict of interest statement
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